Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Funding Amount
$50,000 - $300,000
Deadline
November 10, 2026
20 days left
Number of Awards
13
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- School districts
- City & township governments
- Small businesses
- State governments
- Tribal governments
- Nonprofits (501(c)(3))
- For-profit businesses
- Public colleges & universities
Geography
- Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Overview
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, analyzing, handling, or performing quality control of biospecimens used for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-CA-26-002
- Total Funding: $4,500,000
- Expected Awards: 9
- Instrument: grant
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Focus Areas & Funding Uses
Fields of Work
- Science research
- Cancer
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required)
National Institutes of Health
Amount
$1,500,000 total
Deadline
October 22, 2026
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
October 30, 2026
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
National Institutes of Health
Amount
$2,000,000 total
Deadline
October 30, 2026
GREGoRi Innovation Projects (U01 Clinical Trial Optional)
National Institutes of Health
Amount
$3 – $500K
Deadline
October 30, 2026
GREGoRi Technology Integration Center (U01, Clinical Trials Optional)
National Institutes of Health
Amount
$3,000,000 total
Deadline
October 30, 2026
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Ready to apply for Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed). Now let's win it.